Afrânio Côgo Destefani
Afrânio Côgo Destefani has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Vinícius Côgo Destefani
Molecular Dynamics and Modeling Laboratory (DynMolLab)
4 shared publicationsBianca Vitrio
Molecular Dynamics and Modeling Laboratory (DynMolLab)
2 shared publicationsAfrânio Côgo
Federal University of Espírito Santo Brasil
1 shared publication- Ana Claudia Hertel Pereira
Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), Vila Velha, ES, Brazil
1 shared publication - Arícia Leone Evangelista Monteiro de Assis
High Complexity Center, Instituto Galzu, Campos dos Goytacazes 28110-000, RJ, Brazil
1 shared publication - Beatriz Peters Pereira
Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), Vila Velha, ES, Brazil
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by Springer Nature in Cureus
- Vol. 18 (8) , e115344
Human-Governed Validation of Artificial Intelligence-Generated Medical Assessment Artifacts: A Technical Report
Generative artificial intelligence (AI) models can create fluent medical assessment materials, including multiple-choice questions, distractors, clinical vignettes, answer explanations, and blueprint tags. However, linguistic plausibility does not establish measurement validity. Using AI-generated text as ready-made assessment material may introduce risks related to clinical accuracy, item-writing quality, blueprint alignment, distractor functioning, fairness, and score interpretation. This technical report presents a human-governed validation workflow that treats AI-generated medical assessment artifacts as candidates requiring staged review rather than immediate deployment. The workflow is organized into seven gates: artifact taxonomy, AI provenance and human accountability, clinical and content review, item-writing and language review, blueprint alignment, psychometric-readiness decision, and final human approval. The psychometric-readiness gate explicitly asks whether item analysis, distractor analysis, differential item functioning (DIF) review, or other empirical evaluation is required before an artifact is used in a scored assessment. By separating expert clinical review from psychometric evidence, the workflow preserves human accountability while acknowledging that expert approval alone cannot support all score-based interpretations. We recommend introducing AI-generated assessment materials into medical education pipelines as preliminary candidates subject to documented governance, human oversight, and empirical evaluation when used for scored or consequential assessment.
- 28 August 2026
- Published by Springer Nature in Cureus
- Vol. 18 (8) , e115344
Open AccessHuman-Governed Validation of Artificial Intelligence-Generated Medical Assessment Artifacts: A Technical Report
Generative artificial intelligence (AI) models can create fluent medical assessment materials, including multiple-choice questions, distractors, clinical vignettes, answer explanations, and blueprint tags. However, linguistic plausibility does not establish measurement validity. Using AI-generated text as ready-made assessment material may introduce risks related to clinical accuracy, item-writing quality, blueprint alignment, distractor functioning, fairness, and score interpretation. This technical report presents a human-governed validation workflow that treats AI-generated medical assessment artifacts as candidates requiring staged review rather than immediate deployment. The workflow is organized into seven gates: artifact taxonomy, AI provenance and human accountability, clinical and content review, item-writing and language review, blueprint alignment, psychometric-readiness decision, and final human approval. The psychometric-readiness gate explicitly asks whether item analysis, distractor analysis, differential item functioning (DIF) review, or other empirical evaluation is required before an artifact is used in a scored assessment. By separating expert clinical review from psychometric evidence, the workflow preserves human accountability while acknowledging that expert approval alone cannot support all score-based interpretations. We recommend introducing AI-generated assessment materials into medical education pipelines as preliminary candidates subject to documented governance, human oversight, and empirical evaluation when used for scored or consequential assessment.
- Open Access
- 1 August 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (8) , 4312-4331
ADVANCING CARDIOVASCULAR CARE: A COMPREHENSIVE REVIEW OF PORTABLE AND CONTINUOUS MONITORING DEVICES IN CARDIOVASCULAR RADIOLOGY
Cardiovascular radiology has witnessed significant advancements with the introduction and widespread adoption of portable and continuous monitoring devices. These technologies have revolutionized patient care by providing real-time, comprehensive cardiovascular health assessments. This narrative review explores the current landscape of portable and continuous monitoring devices in cardiovascular radiology. It examines their applications, impact on early detection of complications, influence on mortality rates, and potential side effects associated with prolonged use. By synthesizing recent research and clinical guidelines, this review aims to thoroughly understand these devices' role in modern cardiovascular care and their potential to shape future diagnostic and treatment paradigms.
- 1 August 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (8) , 4312-4331
Open AccessADVANCING CARDIOVASCULAR CARE: A COMPREHENSIVE REVIEW OF PORTABLE AND CONTINUOUS MONITORING DEVICES IN CARDIOVASCULAR RADIOLOGY
Cardiovascular radiology has witnessed significant advancements with the introduction and widespread adoption of portable and continuous monitoring devices. These technologies have revolutionized patient care by providing real-time, comprehensive cardiovascular health assessments. This narrative review explores the current landscape of portable and continuous monitoring devices in cardiovascular radiology. It examines their applications, impact on early detection of complications, influence on mortality rates, and potential side effects associated with prolonged use. By synthesizing recent research and clinical guidelines, this review aims to thoroughly understand these devices' role in modern cardiovascular care and their potential to shape future diagnostic and treatment paradigms.
- Open Access
- 1 August 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (8) , 3962-3983
Advancing Neuroimaging Frontiers: A Comprehensive Review of Novel Diagnostic Techniques in Neuroradiology and Their Clinical Applications
The review article provides a comprehensive overview of the latest advancements in neuroradiological techniques and their clinical applications. It explores various advanced magnetic resonance imaging (MRI) methods, including diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), perfusion-weighted imaging (PWI), functional MRI (fMRI), and magnetic resonance spectroscopy (MRS), as well as developments in computed tomography (CT) technology, such as multidetector CT (MDCT) and dual-energy CT (DECT). The article discusses the principles, applications, and limitations of these techniques, highlighting their impact on patient care, particularly in diagnosing and managing neurological conditions, including cerebrovascular diseases, brain tumors, neurodegenerative disorders, and traumatic brain injuries. The review also addresses the challenges and potential future directions in neuroradiology.
- 1 August 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (8) , 3962-3983
Open AccessAdvancing Neuroimaging Frontiers: A Comprehensive Review of Novel Diagnostic Techniques in Neuroradiology and Their Clinical Applications
The review article provides a comprehensive overview of the latest advancements in neuroradiological techniques and their clinical applications. It explores various advanced magnetic resonance imaging (MRI) methods, including diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), perfusion-weighted imaging (PWI), functional MRI (fMRI), and magnetic resonance spectroscopy (MRS), as well as developments in computed tomography (CT) technology, such as multidetector CT (MDCT) and dual-energy CT (DECT). The article discusses the principles, applications, and limitations of these techniques, highlighting their impact on patient care, particularly in diagnosing and managing neurological conditions, including cerebrovascular diseases, brain tumors, neurodegenerative disorders, and traumatic brain injuries. The review also addresses the challenges and potential future directions in neuroradiology.
- Open Access
- 1 August 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (8) , 1625-1636
Rheumatoid Arthritis Treatment: Harnessing Novel Molecular Targets and Therapeutics for Improved Patient Outcomes
Rheumatoid arthritis (RA) is a chronic autoimmune disease that has significant unmet needs for improved treatment outcomes. This review provides an overview of emerging molecular targets and potential new therapies for managing RA. The discussed targets, such as CD40-CD40 ligand, programmed death protein 1 (PD-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor-associated kinases (IRAKs), tyrosine kinase 2 (TYK2), bradykinin receptor 1 (B1R), and OX40-OX40 ligand, have shown promising results in preclinical studies and clinical trials. These findings stimulate continued efforts to develop more effective and safer therapeutic options, encouraging stakeholders to contribute to improving RA management.
- 1 August 2024
- Published by Brazilian Journal of Implantology and Health Sciences in Brazilian Journal of Implantology and Health Sciences
- Vol. 6 (8) , 1625-1636
Open AccessRheumatoid Arthritis Treatment: Harnessing Novel Molecular Targets and Therapeutics for Improved Patient Outcomes
Rheumatoid arthritis (RA) is a chronic autoimmune disease that has significant unmet needs for improved treatment outcomes. This review provides an overview of emerging molecular targets and potential new therapies for managing RA. The discussed targets, such as CD40-CD40 ligand, programmed death protein 1 (PD-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor-associated kinases (IRAKs), tyrosine kinase 2 (TYK2), bradykinin receptor 1 (B1R), and OX40-OX40 ligand, have shown promising results in preclinical studies and clinical trials. These findings stimulate continued efforts to develop more effective and safer therapeutic options, encouraging stakeholders to contribute to improving RA management.
- Open Access
- 4 April 2024
- Published by Revista CPAQV in Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
- Vol. 16 (2)
ADVANCEMENTS IN OSTEOGENESIS IMPERFECTA TREATMENT: FROM GENETICS TO PERSONALIZED THERAPIES
Osteogenesis imperfecta (OI) is a complex genetic disorder characterized by fragile bones and frequent fractures. It is primarily caused by mutations affecting collagen type I production. Recent advancements in genetic research have identified multiple genes involved in the disorder, broadening the scope of potential targeted therapies. This narrative review synthesizes the latest developments in the management and treatment of OI, focusing on personalized therapeutic interventions.OI is classified into several types based on genetic mutations, each with distinct clinical manifestations. Most cases are linked to mutations in the COL1A1 and COL1A2 genes, which directly affect collagen quality and the bone matrix structure. Emerging therapies explored in this review include bisphosphonates, genetic engineering techniques such as CRISPR/Cas9, and novel pharmacological agents targeting specific molecular pathways involved in bone metabolism and repair. Recent studies have shown promising results in using gene therapy to correct defective genes and employing targeted drug therapies to modulate bone formation and resorption processes. These advancements underscore the potential of personalized medicine in providing more effective management strategies for patients with OI.The genetic heterogeneity of OI necessitates a multifaceted approach to treatment that encompasses both the correction of genetic defects and the modulation of bone metabolism pathways. Innovations in genetic engineering and drug therapy are paving the way for more tailored and effective treatments, which promise to significantly improve the quality of life for individuals with OI. Ongoing research and clinical trials are crucial for furthering our understanding of the disease mechanisms and developing safer, more effective therapeutic options.
- 4 April 2024
- Published by Revista CPAQV in Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
- Vol. 16 (2)
Open AccessADVANCEMENTS IN OSTEOGENESIS IMPERFECTA TREATMENT: FROM GENETICS TO PERSONALIZED THERAPIES
Osteogenesis imperfecta (OI) is a complex genetic disorder characterized by fragile bones and frequent fractures. It is primarily caused by mutations affecting collagen type I production. Recent advancements in genetic research have identified multiple genes involved in the disorder, broadening the scope of potential targeted therapies. This narrative review synthesizes the latest developments in the management and treatment of OI, focusing on personalized therapeutic interventions.OI is classified into several types based on genetic mutations, each with distinct clinical manifestations. Most cases are linked to mutations in the COL1A1 and COL1A2 genes, which directly affect collagen quality and the bone matrix structure. Emerging therapies explored in this review include bisphosphonates, genetic engineering techniques such as CRISPR/Cas9, and novel pharmacological agents targeting specific molecular pathways involved in bone metabolism and repair. Recent studies have shown promising results in using gene therapy to correct defective genes and employing targeted drug therapies to modulate bone formation and resorption processes. These advancements underscore the potential of personalized medicine in providing more effective management strategies for patients with OI.The genetic heterogeneity of OI necessitates a multifaceted approach to treatment that encompasses both the correction of genetic defects and the modulation of bone metabolism pathways. Innovations in genetic engineering and drug therapy are paving the way for more tailored and effective treatments, which promise to significantly improve the quality of life for individuals with OI. Ongoing research and clinical trials are crucial for furthering our understanding of the disease mechanisms and developing safer, more effective therapeutic options.
- Open Access
- 1 March 2024
- Published by Brazilian Journals in REVISTA FOCO
- Vol. 17 (3) , e4542
EPILEPSIA INFANTIL: PRINCIPAIS IMPACTOS NO AMBIENTE ESCOLAR
A epilepsia é caracterizada por atividade elétrica cerebral anormal e temporária que causa inúmeros prejuízos às crianças que a possuem. No âmbito estudantil estas enfrentam prejuízos que crianças neurotípicas não enfrentam, por isso é importante entendê-los para que sejam eficientemente mitigados. O estudo lista, por meio de uma revisão sistemática integrativa sobre tais aspectos, como essas crianças são impactadas.
- 1 March 2024
- Published by Brazilian Journals in REVISTA FOCO
- Vol. 17 (3) , e4542
Open AccessEPILEPSIA INFANTIL: PRINCIPAIS IMPACTOS NO AMBIENTE ESCOLAR
A epilepsia é caracterizada por atividade elétrica cerebral anormal e temporária que causa inúmeros prejuízos às crianças que a possuem. No âmbito estudantil estas enfrentam prejuízos que crianças neurotípicas não enfrentam, por isso é importante entendê-los para que sejam eficientemente mitigados. O estudo lista, por meio de uma revisão sistemática integrativa sobre tais aspectos, como essas crianças são impactadas.
- Open Access
- 10 January 2024
- Published by Revista CPAQV in Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
- Vol. 16 (1) , 8
AVANÇOS NA TERAPIA COM CÉLULAS CAR-T PARA LEUCEMIA LINFOBLÁSTICA AGUDA EM PEDIATRIA: UM ENFOQUE EM EFETIVIDADE CLÍNICA E PERSPECTIVAS FUTURAS
A leucemia linfoblástica aguda (LLA) é o câncer mais comum na infância, representando uma parte significativa das leucemias pediátricas. Apesar dos avanços na quimioterapia, uma proporção substancial de pacientes pediátricos ainda enfrenta recidiva ou resistência ao tratamento. A terapia com células CAR-T (Chimeric Antigen Receptor T-cell) surgiu como uma abordagem inovadora para neoplasias hematológicas refratárias e recidivantes. Este estudo tem como objetivo avaliar a eficácia e segurança da terapia com células CAR-T no tratamento de LLA em crianças. Foram incluídos estudos publicados nos últimos dez anos que investigaram a eficácia da terapia em pacientes pediátricos com LLA. Os resultados mostraram que a terapia CAR-T alcança taxas de remissão completa entre 70% e 90%, com uma sobrevida livre de doença de 50% a 70% e uma sobrevida global de 55% a 75%. Embora a síndrome de liberação de citocinas (SLC) e a neurotoxicidade tenham sido observadas em 35% e 15% dos casos, respectivamente, a maioria dos eventos adversos foi manejável com intervenções clínicas adequadas. A comparação com tratamentos convencionais revelou que a terapia CAR-T proporciona uma eficácia superior e um perfil de toxicidade mais favorável. Conclui-se que a terapia CAR-T é uma opção promissora para o tratamento da LLA pediátrica, embora desafios relacionados à produção, custo e gerenciamento de efeitos adversos ainda precisem ser superados. A continuidade da pesquisa é essencial para otimizar esta terapia e expandir seu acesso.
- 10 January 2024
- Published by Revista CPAQV in Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
- Vol. 16 (1) , 8
Open AccessAVANÇOS NA TERAPIA COM CÉLULAS CAR-T PARA LEUCEMIA LINFOBLÁSTICA AGUDA EM PEDIATRIA: UM ENFOQUE EM EFETIVIDADE CLÍNICA E PERSPECTIVAS FUTURAS
A leucemia linfoblástica aguda (LLA) é o câncer mais comum na infância, representando uma parte significativa das leucemias pediátricas. Apesar dos avanços na quimioterapia, uma proporção substancial de pacientes pediátricos ainda enfrenta recidiva ou resistência ao tratamento. A terapia com células CAR-T (Chimeric Antigen Receptor T-cell) surgiu como uma abordagem inovadora para neoplasias hematológicas refratárias e recidivantes. Este estudo tem como objetivo avaliar a eficácia e segurança da terapia com células CAR-T no tratamento de LLA em crianças. Foram incluídos estudos publicados nos últimos dez anos que investigaram a eficácia da terapia em pacientes pediátricos com LLA. Os resultados mostraram que a terapia CAR-T alcança taxas de remissão completa entre 70% e 90%, com uma sobrevida livre de doença de 50% a 70% e uma sobrevida global de 55% a 75%. Embora a síndrome de liberação de citocinas (SLC) e a neurotoxicidade tenham sido observadas em 35% e 15% dos casos, respectivamente, a maioria dos eventos adversos foi manejável com intervenções clínicas adequadas. A comparação com tratamentos convencionais revelou que a terapia CAR-T proporciona uma eficácia superior e um perfil de toxicidade mais favorável. Conclui-se que a terapia CAR-T é uma opção promissora para o tratamento da LLA pediátrica, embora desafios relacionados à produção, custo e gerenciamento de efeitos adversos ainda precisem ser superados. A continuidade da pesquisa é essencial para otimizar esta terapia e expandir seu acesso.
- Open Access
- 9 November 2019
- Published by KenzPub in Nuclear Receptor Research
- Vol. 6
SLICC 12 Criteria Are More Effectiveness than ACR 97 Score about Systemic Lupus Erythematosus Diagnosis
Introduction: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease wich variable symptoms affecting numerous organs and insidious onset of an unpredictable course, with episodes of activity and remission. The development of the disease is evaluated by a combination of clinical history, physical and laboratory tests to identify risk factors related to the stage or complications of the disease. The American College of Rheumatology (ACR 97) was the first to establish criteria for SLE classification. In 2012, The Systemic Lupus International Collaborating Clinics (SLICC 12) published a new set of criteria aimed at optimizing the classification of SLE. Objectives: Compare the criteria proposed by ACR 97 and SLICC 12 for the diagnosis of SLE and to gather information on clinical characteristics, diagnosis, and treatment. Methodology: Literature review, using the PubMed-NCBI database. The inclusion criteria were: articles published in the last five years; study in humans and selection by the direct relation with the selected theme. Results: SLICC 12 demonstrated a higher sensitivity diagnosed in reports compared with as ACR 97. Conclusion: We found that SLICC 12 is the classification criterion for SLE presenting the most excellent variety of laboratory, cutaneous, immunological and neuropsychiatric findings, allowing a better performance of the classification of patients with SLE and thus the early diagnosis of the disease.
- 9 November 2019
- Published by KenzPub in Nuclear Receptor Research
- Vol. 6
Open AccessSLICC 12 Criteria Are More Effectiveness than ACR 97 Score about Systemic Lupus Erythematosus Diagnosis
Introduction: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease wich variable symptoms affecting numerous organs and insidious onset of an unpredictable course, with episodes of activity and remission. The development of the disease is evaluated by a combination of clinical history, physical and laboratory tests to identify risk factors related to the stage or complications of the disease. The American College of Rheumatology (ACR 97) was the first to establish criteria for SLE classification. In 2012, The Systemic Lupus International Collaborating Clinics (SLICC 12) published a new set of criteria aimed at optimizing the classification of SLE. Objectives: Compare the criteria proposed by ACR 97 and SLICC 12 for the diagnosis of SLE and to gather information on clinical characteristics, diagnosis, and treatment. Methodology: Literature review, using the PubMed-NCBI database. The inclusion criteria were: articles published in the last five years; study in humans and selection by the direct relation with the selected theme. Results: SLICC 12 demonstrated a higher sensitivity diagnosed in reports compared with as ACR 97. Conclusion: We found that SLICC 12 is the classification criterion for SLE presenting the most excellent variety of laboratory, cutaneous, immunological and neuropsychiatric findings, allowing a better performance of the classification of patients with SLE and thus the early diagnosis of the disease.
- 1 July 2017
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 206, 65-72
Chronic administration of antioxidant resin from Virola oleifera attenuates atherogenesis in LDLr -/- mice
- 1 July 2017
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 206, 65-72
Chronic administration of antioxidant resin from Virola oleifera attenuates atherogenesis in LDLr -/- mice
- Open Access
- 5 June 2017
- Published by Juniper Publishers in JOJ Urology & Nephrology
- Vol. 3 (2)
Update on Renal Function Assessment
International journal of nephrology is an Open Access, peer-reviewed international journal that provides current information of research, development and treatment aspects that are involved in the fields of urology and nephrology. Urology is the branch of medicine
- 5 June 2017
- Published by Juniper Publishers in JOJ Urology & Nephrology
- Vol. 3 (2)
Open AccessUpdate on Renal Function Assessment
International journal of nephrology is an Open Access, peer-reviewed international journal that provides current information of research, development and treatment aspects that are involved in the fields of urology and nephrology. Urology is the branch of medicine